Ana Saavedra-Mendez, APRN
Family · Fort Worth, TXNPI 1083356091
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $689, more than ten times the $37 reported in 2022.
Across 85 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$349
- Lilly USA, LLC$332
- Novo Nordisk$212
- AstraZeneca$203
- Amgen$150
- Exact Sciences$103
- plus $317 from 10 others
What the payments were for
- Food & beverage$1,666100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 14 | $349 |
| Lilly USA, LLC | 19 | $332 |
| Novo Nordisk | 11 | $212 |
| AstraZeneca | 11 | $203 |
| Amgen | 8 | $150 |
| Exact Sciences | 6 | $103 |
| Pfizer | 3 | $57 |
| Dexcom, Inc. | 3 | $57 |
| GSK | 2 | $42 |
| Hologic Sales And Service, LLC | 1 | $42 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $17 |
| CSL Behring | 1 | $16 |
| AbbVie | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$1,666 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $241 |
| Alendronate Sodium | 11 | $109 |
| CefuroximeCefuroxime Axetil | 11 | $88 |
| Pantoprazole Sodium | 11 | $87 |
| Atorvastatin Calcium | 14 | $81 |
Paid to pharmacies, not to this prescriber.
Other family in Fort Worth
- Laura MoeFort Worth$158K
- Julie TaylorFort Worth$63K
- Ryan BourgeoisFort Worth$37K
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.